Tevogen Bio secures $6 million in Series C preferred stock
WARREN, NJ, Aug. 22, 2024 (GLOBE NEWSWIRE) — Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics for oncology, neurology and virology, has entered into a…
Two studies show how immunotherapies together activate immune responses in melanoma
Two studies published in the latest issue of the journal cell Researchers at the University of Pittsburgh have discovered how immunotherapies that target the immune checkpoints PD1 and LAG3 work together to activate immune responses. The findings shed light on…
